CDC vs XEL

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on CDC as a result. In 70 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for CDC just turned positive on October 07, 2026. Looking at past instances where CDC's MACD turned positive, the stock continued to rise in 45 of 53 cases over the following month. The odds of a continued upward trend are 85%.

The 10-day moving average for CDC crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

Following a +1.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDC advanced for three days, in 269 of 347 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

The Aroon Indicator entered an Uptrend today. In 280 of 364 cases where CDC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.

Bearish Trend Analysis

The 10-day RSI Indicator for CDC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 27 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 66 cases where CDC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

CDC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on XEL as a result. In 47 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.

XEL moved above its 50-day moving average on October 13, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +3.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where XEL advanced for three days, in 172 of 332 cases, the price rose further within the following month. The odds of a continued upward trend are 52%.

The Aroon Indicator entered an Uptrend today. In 110 of 251 cases where XEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 44%.

Bearish Trend Analysis

The 10-day RSI Indicator for XEL moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 16 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 67 cases where XEL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 42%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.

XEL broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. XEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 40 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 50, placing this stock slightly better than average.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.069) is normal, around the industry mean (2.019). P/E Ratio (21.708) is within average values for comparable stocks, (14.939). Projected Growth (PEG Ratio) (1.744) is also within normal values, averaging (1.785). Dividend Yield (0.030) settles around the average of (0.054) among similar stocks. P/S Ratio (3.042) is also within normal values, averaging (187.392).

The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 70 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.